2022
Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchMeSH KeywordsBile Duct NeoplasmsBile Ducts, IntrahepaticCholangiocarcinomaCholangitis, SclerosingHumansRisk FactorsConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areas
2017
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine
Carbone M, Cristoferi L, Cortesi PA, Rota M, Ciaccio A, Okolicsanyi S, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Belli LS, Munari LM, Mantovani L, Strazzabosco M. Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2017, 1864: 1415-1422. PMID: 28844954, DOI: 10.1016/j.bbadis.2017.08.025.Peer-Reviewed Original ResearchConceptsClinical outcome indicatorsAutoimmune liver diseaseLiver diseaseMajor autoimmune liver diseasesTertiary clinical centersPrimary sclerosing cholangitisPrimary biliary cholangitisDifferent clinical outcomesNatural history studiesValue of careAutoimmune hepatitisClinical practice environmentJesus BanalesMarco MarzioniNicholas LaRussoPeter JansenSclerosing cholangitisBiliary cholangitisConsecutive patientsClinical outcomesMedian timeCare pathwayClinical centersClinical strategiesValue-based medicinePathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium
Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E, Scirpo R, Fabris L. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2017, 1864: 1374-1379. PMID: 28754453, PMCID: PMC5785585, DOI: 10.1016/j.bbadis.2017.07.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsToll-like receptorsLiver damageCystic fibrosis-related liver diseaseInnate immunityDamage-associated molecular patternsEpithelial innate immunityPro-inflammatory behaviorBiliary epithelial cellsNumber of receptorsJesus BanalesMarco MarzioniNicholas LaRussoPeter JansenLiver injuryLiver diseaseBile flowInflammatory processBiliary epitheliumInflammatory responsePathophysiologic implicationsReparative processesNumber of evidencesFirst defense lineCholangiocytesMolecular patterns
2015
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat
Bonato G, Cristoferi L, Strazzabosco M, Fabris L. Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat. Digestive Diseases 2015, 33: 140-148. PMID: 26641079, PMCID: PMC4939833, DOI: 10.1159/000440826.Peer-Reviewed Original ResearchMeSH KeywordsBile Duct NeoplasmsCholangiocarcinomaCholangitis, SclerosingColorectal NeoplasmsGallbladder NeoplasmsHumansInflammatory Bowel DiseasesNeoplasmsConceptsInflammatory bowel diseaseUlcerative colitisEffective medical treatmentGallbladder carcinomaColorectal carcinomaUnknown etiologyEarly diagnosisMedical treatmentChronic inflammatory liver diseaseManagement of PSCInflammatory liver diseasePrimary sclerosing cholangitisGroup of patientsChronic inflammatory conditionsChronic inflammatory diseaseBile duct systemRisk of cancerDevelopment of malignancyEffective surveillance strategiesExtensive histologicLiver transplantationNeoadjuvant chemoradiotherapySclerosing cholangitisFeared complicationFrequent complication
2014
Characterization of animal models for primary sclerosing cholangitis (PSC)
Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, Keitel V, Schramm C, Marschall HU, Karlsen TH, Melum E, Kaser A, Eksteen B, Strazzabosco M, Manns M, Trauner M, Group I. Characterization of animal models for primary sclerosing cholangitis (PSC). Journal Of Hepatology 2014, 60: 1290-1303. PMID: 24560657, PMCID: PMC4517670, DOI: 10.1016/j.jhep.2014.02.006.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisAnimal modelsEnd-stage liver diseaseStage liver diseaseDevelopment of cholestasisNew treatment strategiesEffective medical treatmentLiver transplantationSclerosing cholangitisBiliary fibrosisChronic cholangiopathiesLiver diseaseTreatment strategiesStudy groupHigh riskPathogenetic conceptsMedical treatmentFrequent needCholangitisCholangiopathyCholestasisPoor understandingTransplantationFibrosisGroup
2010
Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C
Hov JR, Lleo A, Selmi C, Woldseth B, Fabris L, Strazzabosco M, Karlsen TH, Invernizzi P. Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. Journal Of Hepatology 2010, 52: 712-717. PMID: 20347497, DOI: 10.1016/j.jhep.2009.11.029.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCholangitis, SclerosingChromosome MappingChromosomes, Human, Pair 6EuropeFemaleGene FrequencyHLA-B AntigensHLA-C AntigensHLA-DR AntigensHLA-DRB1 ChainsHumansInflammatory Bowel DiseasesItalyLiver CirrhosisMaleMicrosatellite RepeatsMiddle AgedReference ValuesRisk AssessmentYoung AdultConceptsPrimary sclerosing cholangitisSclerosing cholangitisHLA-DRB1Risk of PSCTNF-alpha -308GNatural killer cellsP-valueChi-square testHLA-C2PSC patientsKiller cellsTumor necrosisPSC pathogenesisT lymphocytesSignificant associationAbstractTextMICA locusHLA complexHLADRB1CholangitisUncorrected p-valueKIRFurther studiesAIMS
2008
Incidence and Management of Colorectal Cancer in Liver Transplant Recipients
Nishihori T, Strazzabosco M, Saif MW. Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer 2008, 7: 260-266. PMID: 18650194, PMCID: PMC3755274, DOI: 10.3816/ccc.2008.n.033.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsTransplant recipientsColorectal cancerLiver transplantationPatient populationColon cancerDe novo colorectal cancerDe novo malignanciesLong-term immunosuppressionMetastatic colorectal cancerPrimary sclerosing cholangitisInflammatory bowel diseaseMajor health concernChronic rejectionNovo malignanciesProlonged immunosuppressionSclerosing cholangitisPosttransplantation periodBiologic agentsBowel diseaseCombination chemotherapyProphylactic colectomyOverall incidenceCommon malignancyLymphoproliferative disease
2003
Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population
Neri T, Cavestro G, Seghini P, Zanelli P, Zanetti A, Savi M, Podda M, Zuin M, Colombo M, Floreani A, Rosina F, Porro G, Strazzabosco M, Okolicsanyi L. Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Digestive And Liver Disease 2003, 35: 571-576. PMID: 14567462, DOI: 10.1016/s1590-8658(03)00274-3.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisHLA-DRB1PSC patientsSclerosing cholangitisFrequency of patientsFrequency of DRB1Tumor necrosis factorPolymerase chain reaction-based methodologyMHC region genesNecrosis factorHLA haplotypeHLA-DQB1T polymorphismNormal controlsPatientsDRB1CFTR geneMajor histocompatibility complex (MHC) genesHLA regionHaplotype frequenciesSouthern European populationsCystic fibrosis transmembrane conductance regulator (CFTR) geneCholangitisDNA levelsHomozygous genotype